NMPA (formerly CFDA) regulates the registration, manufacture, import, and post-market surveillance of medical devices in mainland China through a three-class risk-based framework. Under China's Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739), devices are classified into Class I, II and III. Class I products are filed, while Class II and III products need registration, with imported Class II and III devices registered with the NMPA. Registration often requires type testing in Chinese accredited labs and clinical evaluation, which can sometimes be met through equivalence or exemption lists.

Why it matters

Most Class II and III devices require in-country clinical evaluation or trials, type testing at NMPA-designated labs, and a local agent. Recent reforms have introduced an innovative-device fast track and accept some overseas data.

Common pitfalls

•A common pitfall is underestimating the need for local representation and testing, which are often mandatory for foreign manufacturers.
•Manufacturers sometimes misunderstand the specific criteria for the "innovative device" fast track, leading to incorrect application strategies.
•Failing to keep up with frequently updated NMPA regulations and guidance documents can result in compliance issues.
•Assuming that international certifications or clinical data are always directly accepted without NMPA-specific review or bridging studies is a frequent mistake.
•Inadequate preparation for NMPA on-site audits and inspections can lead to delays or non-compliance findings.

Sources

NMPA English portal · NMPA
FDA - Medical Devices · FDA
European Commission - Medical Devices · European Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.